Correlates of Heroin Use, Pharmaceutical Fentanyl Misuse, and Dual Heroin-Fentanyl Use: Evidence from the U.S.
fentanyl
health
heroin
opioids
risk
Journal
Drugs, habits and social policy
ISSN: 2752-6747
Titre abrégé: Drugs Habits Soc Policy
Pays: England
ID NLM: 9918282681206676
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
medline:
27
4
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
ppublish
Résumé
The emergence of fentanyl has deepened concerns about the opioid crisis. The shift has created new distinctions in patterns of opioid use, which may be important for prevention and intervention. We examine socio-demographic correlates as well as health and substance use characteristics of different groups of opioid users. We utilized the 2015-2019 National Survey on Drug Use and Health to examine distinctions between groups (n=11,142) of individuals who misuse prescription opioids, use heroin but not fentanyl, misuse pharmaceutical fentanyl but not heroin, and use both heroin and fentanyl. Multinomial and logistic regression models were used to identify these distinctions. Few socio-demographic differences emerged between the prescription opioid group and pharmaceutical fentanyl misuse group. While those who misuse fentanyl have higher odds of using other drugs and experiencing certain mental health problems than those misusing prescription pills, both the heroin and fentanyl-heroin use groups reported considerably poorer health and substance use indicators relative to those who solely misuse fentanyl. It is also notable that both heroin use groups are more highly associated with cocaine and methamphetamine use than those misusing fentanyl alone. This study highlights distinctions between pharmaceutical fentanyl users, heroin users, and users of both substances. While we identify important distinctions between the opioid use groups studied, individuals using both heroin and pharmaceutical fentanyl report the poorest health and substance use characteristics. Important differences between the fentanyl-only group and the group who consume both drugs may have implications for prevention, intervention, and clinical work amidst shifting patterns of opioid use.
Identifiants
pubmed: 37101522
doi: 10.1108/dhs-04-2022-0019
pmc: PMC10128616
mid: NIHMS1844752
doi:
Types de publication
Journal Article
Langues
eng
Pagination
14-25Subventions
Organisme : NIDA NIH HHS
ID : R21 DA046447
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest: All authors have indicated they have no potential conflicts of interest to disclose. The authors alone are responsible for the contents of the paper.
Références
Drug Alcohol Rev. 2022 Feb;41(2):435-443
pubmed: 34628699
Addict Behav. 2019 Sep;96:89-93
pubmed: 31063940
JAMA Netw Open. 2020 Jan 3;3(1):e1918514
pubmed: 31899527
Am J Drug Alcohol Abuse. 2020 Sep 2;46(5):625-631
pubmed: 32689810
Addiction. 1996 Mar;91(3):405-11
pubmed: 8867202
Addiction. 2019 Feb;114(2):259-267
pubmed: 30276902
Int J Drug Policy. 2019 Sep;71:183-188
pubmed: 30718120
Drug Alcohol Rev. 2008 Nov;27(6):625-32
pubmed: 19378446
Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350
pubmed: 33965972
Addict Behav. 2015 Sep;48:71-8
pubmed: 26004857
Int J Drug Policy. 2017 Aug;46:107-111
pubmed: 28735776
Drug Alcohol Depend. 2020 Mar 1;208:107779
pubmed: 31931266
Drug Alcohol Rev. 2018 Apr;37 Suppl 1:S314-S322
pubmed: 29405465
Drug Alcohol Depend. 2021 Oct 1;227:109003
pubmed: 34482046
Addiction. 2021 Oct;116(10):2600-2609
pubmed: 33651441
Drug Alcohol Depend. 2020 Jun 3;213:108089
pubmed: 32531703
Addict Behav. 2017 May;68:35-38
pubmed: 28088741
Addict Behav. 2015 Dec;51:106-12
pubmed: 26253938
Drug Alcohol Depend. 2021 Oct 1;227:109001
pubmed: 34492555
Drug Alcohol Rev. 2013 May;32(3):269-75
pubmed: 23442164
Drug Alcohol Depend. 2020 Sep 1;214:108162
pubmed: 32652380
Drug Alcohol Depend. 2019 May 1;198:28-33
pubmed: 30877954
Drug Alcohol Depend. 2021 Jan 1;218:108416
pubmed: 33278761